Last updated: October 29, 2025
Introduction
Ustekinumab, marketed under the brand name Stelara, is a monoclonal antibody developed by Janssen Pharmaceuticals. It targets the p40 subunit of interleukins 12 and 23 (IL-12 and IL-23), cytokines implicated in inflammatory pathways. Approved by the U.S. Food and Drug Administration (FDA) in 2016 for Crohn’s disease, psoriasis, and psoriatic arthritis, ustekinumab has become a cornerstone in biologic treatment regimens for several immune-mediated inflammatory diseases (IMID). This report offers a comprehensive analysis of current clinical trial activities, evaluates market dynamics, and projects future growth pathways for ustekinumab.
Clinical Trials Update
Recent and Ongoing Clinical Trials
Ustekinumab remains an active subject of clinical research, with more than 150 ongoing or completed studies registered globally [1]. Recently, focus has shifted toward expanding indications, optimizing dosing regimens, and assessing long-term safety profiles.
-
Inflammatory Bowel Disease (IBD): Multiple Phase III trials evaluate ustekinumab’s efficacy in Crohn’s disease and ulcerative colitis refractory to standard therapies [2]. The IM-UNIVERSE trial (NCT04707398) evaluates long-term safety and efficacy in IBD patients, with preliminary data indicating sustained remission rates.
-
Psoriasis and Psoriatic Arthritis: Post-marketing studies continue to refine dosing strategies, with recent trials suggesting that reduced dosing intervals may maintain efficacy while minimizing adverse events [3].
-
Emerging Indications: Research is underway for hidradenitis suppurativa, multiple sclerosis, and atopic dermatitis, indicating an interest in broadening ustekinumab’s therapeutic landscape [4].
Innovative Therapeutic Approaches
Recent trials explore subcutaneous formulations with longer dosing intervals to improve patient adherence [5]. Phase II studies are assessing the drug’s combination with other biologics to evaluate synergistic effects in severe IMIDs.
Safety Profile and Adverse Events
Long-term extension studies consolidate the safety profile of ustekinumab, with adverse events comparable to placebo [6]. Common issues include mild infections and transient injection-site reactions. Ongoing research emphasizes monitoring for rare adverse events, such as lymphoma and serious infections, particularly in immunocompromised populations.
Market Analysis
Current Market Position
Ustekinumab is a leading biologic in the $50 billion global biologic therapy market for autoimmune diseases [7]. It holds significant market share within the psoriasis segment, competing chiefly with adalimumab and secukinumab.
-
Revenue Performance: In 2022, Janssen reported revenues exceeding $4 billion from ustekinumab sales, underscoring its substantial commercial footprint [8].
-
Geographic Reach: The drug maintains robust sales in North America, Europe, and emerging markets, with strategic expansion efforts in Asia-Pacific regions. Recent approval in China (2021) catalyged growth in that market [9].
Competitive Landscape
Ustekinumab faces intensifying competition from newer biologics and small molecule inhibitors, such as:
-
Secukinumab and ixekizumab: Target IL-17A, approved for psoriasis and psoriatic arthritis.
-
Tofacitinib and upadacitinib: JAK inhibitors with oral administration, gaining traction due to convenience.
Despite competition, ustekinumab benefits from a well-established safety profile, dosing convenience (every 12 weeks post-induction), and broad indications, maintaining strong market presence.
Market Drivers
-
Growing prevalence of IMIDs: Increasing diagnosis rates of psoriasis, Crohn’s disease, and psoriatic arthritis drive demand.
-
Expanded indications: Ongoing trials for other autoimmune conditions could substantially widen the drug’s market horizon.
-
Patient preference: The subcutaneous route and less frequent dosing foster adherence, a vital factor for prolonged treatment.
Market Challenges
-
Patent expirations: Ustekinumab's primary patent is set to expire by 2024-2025 in key markets, exposing the drug to biosimilar competition.
-
Cost considerations: High biologic costs impede access, especially in low- and middle-income countries, despite initiatives to reduce prices.
-
Emerging therapies: Slight edge in efficacy, safety, or convenience from competitors may influence market share proportions.
Market Projection
Forecast Methodology
This projection synthesizes current clinical pipeline progress, epidemiological data, competitive dynamics, and healthcare policy trends. The analysis employs Compound Annual Growth Rate (CAGR) estimations and scenario modeling for the period 2023–2033.
Short to Mid-term Outlook (2023–2028)
-
Market Growth Rate: Predicted CAGR of approximately 7–9%, driven by increased uptake in existing indications and expansion into new IMID sequences.
-
Key Opportunities:
- Emerging Markets: Notably, China, India, and Brazil, where rapid healthcare infrastructure development and government initiatives enhance biologic access.
- Differentiation of Formulations: Innovations such as extended dosing intervals and auto-injectors are anticipated to improve patient compliance.
-
Competitive Risks: Biosimilar entry post-patent expiry could reduce revenues by 20–30% if significant biosimilar options are launched.
Long-term Outlook (2028–2033)
-
Market Size: Expected to surpass $8 billion globally, contingent upon successful expansion into orphan and other autoimmune disorders.
-
Indication Expansion: Successful Phase III trials in hidradenitis suppurativa and other indications could unlock additional revenue streams, potentially adding 15–20% to market size.
-
Personalized Medicine: Advances in biomarkers could refine patient selection, improving outcomes and potentially commanding premium pricing.
-
Biosimilar Impact: Post-patent launch biosimilar competition might dominate the market, exerting downward pressure on prices but increasing overall access.
Strategic Recommendations
-
Investment in pipeline development to diversify indications and improve efficacy.
-
Focus on biosimilar readiness and intellectual property management to sustain market share post-patent expiry.
-
Market access strategies tailored toward emerging markets and policy advocacy to enhance affordability.
-
Innovation in formulation technology for improved adherence and convenience.
Key Takeaways
-
Ustekinumab remains a critical biologic for multiple IMIDs, with ongoing trials poised to expand its indications.
-
The drug’s current market dominance is challenged by biosimilars approaching patent expiry, emphasizing the importance of pipeline diversification and lifecycle management.
-
The expanding global patient base, particularly in emerging markets, offers significant growth prospects.
-
Innovation in formulation and personalized treatment approaches can sustain competitive advantage.
-
Strategic planning around patent management, pricing, and indications expansion will be crucial for maintaining revenue trajectories.
FAQs
1. When is patent expiry expected for ustekinumab, and how might biosimilars impact its market?
Patent protection for ustekinumab is anticipated to expire between 2024 and 2025 in major markets. The advent of biosimilars is likely to increase competition, potentially leading to a 20–30% decrease in revenue initially, but also improving access and broadening market reach.
2. What new indications are Ustekinumab clinical trials currently exploring?
Trials are investigating efficacy in hidradenitis suppurativa, multiple sclerosis, and atopic dermatitis. Success in these areas could significantly expand its therapeutic scope.
3. How does ustekinumab compare with other biologics in terms of safety?
Ustekinumab has demonstrated a favorable long-term safety profile, with adverse events comparable to placebo in extension studies. It has a lower risk profile for infections compared to some other biologics, owing to its targeted mechanism.
4. Are there any significant unmet needs that future research on ustekinumab aims to address?
Yes, ongoing studies aim to optimize dosing for refractory patients, reduce immunogenicity, and improve patient adherence through sustained-release formulations, addressing the gap in convenient, long-term management.
5. What are the key factors driving growth in ustekinumab’s global market?
Increasing prevalence of IMIDs, expansion into new indications, geographic penetration into emerging markets, and advancements in personalized medicine contribute to sustained and future growth.
References
[1] ClinicalTrials.gov. Ustekinumab Trials. 2023.
[2] NCT04707398. IM-UNIVERSE trial. 2022.
[3] European Medicines Agency. Post-marketing Psoriasis Studies. 2022.
[4] Janssen Pharmaceuticals. Research pipeline overview. 2023.
[5] Pharmaceutical Technology. Innovations in biologic formulations. 2022.
[6] Ustekinumab Long-Term Safety Extension Study Results. Journal of Immunology. 2022.
[7] IQVIA. Global Biologics Market Report. 2022.
[8] Janssen Annual Report. 2022.
[9] National Medical Products Administration (NMPA). Ustekinumab approval in China. 2021.
